Grifols is a global healthcare company that develops, produces, and markets plasma-derived medicines, transfusion medicine solutions, and diagnostic services. Founded in 1909, the company serves patients with chronic, rare, and life-threatening conditions across multiple regions. Its business segments include plasma-derived therapies for neurology, immunology, hepatology, and hematology; diagnostic solutions for disease detection; biological materials for life-science research; and healthcare solutions for hospital pharmacies. Grifols maintains a global network of plasma donation centers in North America, Europe, Africa, the Middle East, and China, where it operates through a partnership with Shanghai RAAS. The company also provides engineering services for biopharmaceutical manufacturing facilities. Key subsidiaries and brands include Biotest, which was acquired in 2021, and Grifols Engineering. Grifols supplies biological materials for clinical trials and the manufacturing of pharmaceutical and diagnostic products, supporting a broad range of therapeutic areas and healthcare operations worldwide.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Drug Manufacturers - General Homepage grifols.com
Sector Healthcare IR page grifols.com/en/home
Tags
plasma-derived medicines, transfusion medicine, diagnostics, biological materials, hospital pharmacy solutions, biopharmaceutical engineering, neurology, immunology, hematology, hepatology, infectious diseases, plasma collection, Biotest, Grifols Engineering, Shanghai RAAS, AMBAR
Press page —

Metrics

Valuation  
Market cap € 7.168B
Market cap (USD) $ 7.877B
P/E 15.94
PEG 0.65
P/BV 0.90
P/S 0.97
P/OCF 6.56
P/FCF 9.17
Dividend yield —
Turnover / mcap —
Returns  
ROE 6.2%
ROI 6.6%
ROIC 13.3%
Profit margin 6.6%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 24.5%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 51
Quality score 29.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2011 FY 2010
Revenue 7.524B 7.212B 6.592B 6.064B 4.933B 5.34B 5.099B 4.487B 4.318B 4.05B 1.796T 990.73B
Net profit 402M 156.92M 59.315M 208.279M 188.726M 618.546M 625.146M 596.642M 662.7M 545.456M 50.228B 115.267B
Free cash flow 782M 669.63M -1.255M -277.358M 349.602M 830.182M 258.55M 505.445M 590.239M 303.862M 83.028B 17.452B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2011 FY 2010
Share price 7.95 6.77 10.62 8.44 9.53 15.78 20.95 15.79 19.51 14.39 — —
Price performance 12m 0.26 -0.36 0.36 -0.24 -0.39 -0.21 0.27 -0.2 0.43 -0.5 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (EUR) 198M 288M 241M 276M 294M 355M 361M 395M 384M 426M
↳ 5y CAGR +5.6% +12.4% +4.6% +10.4% +6.8% +7.7%
Reported Apr 6, 2018 Apr 6, 2018 Apr 5, 2019 Apr 6, 2020 Apr 9, 2021 Apr 29, 2022 Apr 18, 2023 Apr 19, 2024 Apr 11, 2025 Apr 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Item Sequential Page Number Bull 4 Bear 0 Results

1. Third Quarter Results Release, dated November 2, 2026 3

2. Q3 2026 Results Presentation 7

Q3 2026 Financial Results

Grifols increases revenue by 8.4% to EUR 2,040 million and grows net profit by 28% to EUR 162m in Q3’26

● Revenue for the first nine months of 2026 reached EUR 5,614 million, up 4.6% at constant currency (cc), driven by growth in Biopharma

● Adjusted EBITDA for the first nine months reached EUR 1,392 million, up 5.0% cc, with a margin of 24.8%. In the third quarter, adjusted EBITDA totaled EUR 538 million, with a margin of 26.4%

● The company’s net profit reached EUR 162 million in the third quarter, bringing year-to-date net profit through September to EUR 390 million, an increase of 28.4%

● Free cash flow pre-M&A pre-dividends improved by EUR 110 million year-over-year to EUR 298 million, including EUR 208 million in the third quarter

● The net leverage ratio declined to 3.98x, compared with 4.2x in the same period of 2025, while liquidity increased to EUR 2,140 million

● Grifols remains on track to meet its 2026 guidance

● Grifols Egypt is on track to collect approximately one million liters of plasma in 2026

Barcelona, Spain, November 2, 2026 – Grifo

Prompts

GRIFOLS S.A. (ticker GRF), listed in Spain.

ETFs Holding GRIFOLS S.A.

ETF Weight in ETF Shares Market value As of
BSMC 1.43% 336,332 $ 2.381M Jun 30, 2026
BINV 1.29% 893,153 $ 6.324M Jun 30, 2026
DTAN 0.54% 9,218 $ 116.987K Nov 17, 2026
TDI 0.46% 162,608 $ 1.665M Jun 30, 2026
DISV 0.28% 1,083,110 $ 13.976M Nov 12, 2026
DFIS 0.09% 393,558 $ 5.078M Nov 12, 2026
CGIC 0.04% 120,713 $ 1.054M Nov 16, 2026
DXIV 0.03% 6,029 $ 77.795K Nov 12, 2026
DFIC 0.03% 359,561 $ 4.64M Nov 12, 2026
APIE 0.02% 33,836 $ 261.214K Aug 31, 2026
DFAX 0.02% 206,535 $ 2.665M Nov 12, 2026
DFSI 0.02% 16,536 $ 213.372K Nov 12, 2026
NTSI 0.02% 7,516 $ 76.994K Jun 30, 2026
DFAI 0.01% 197,533 $ 2.549M Nov 12, 2026
AVDE 0.00% 25,334 $ 321.656K Nov 16, 2026
AVSD 0.00% 798 $ 10.132K Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
GRFS Common share — US nasdaq 7.31 USD 2026-09-30
GRF canonical Common share — ES bme — —